PacBio on Tuesday announced the launch of two genome sequencing systems, the Revio long-read sequencing system and the Onso short-read sequencing system.
Revio allows customers to sequence up to 1,300 human whole genomes per year at 30-fold coverage for less than $1,000 per genome, PacBio said. It features Nvidia GPUs to provide a 20-fold increase in computing power compared to the firm’s Sequel IIe system.
Revio also integrates deep-learning algorithms to detect DNA methylation from standard sequencing libraries, as well as a Google Health deep-learning method, Deep Consensus, to improve yield and accuracy of HiFi sequencing, PacBio added.
Onso uses PacBio’s sequencing by binding (SBB) technology to provide accurate readings and is designed for compatibility with short-read sequencer products, the firm said.
It supports a variety of library preparation types, single-cell analysis solutions, whole-genome sequencing, amplicon and hybridization capture panels, and other targeted methods, PacBio added.
The company anticipates that the platform will deliver 500 million reads per run and offer 200 and 300 cycle kits for paired- and single-end reads.
“We believe the differentiated accuracy and workflow will allow scientists to process many more samples with the same output as other on-market short-read sequencing platforms,” Mark Van Oene, chief operating officer at PacBio, said in a statement.
Revio has a list price of $779,000 and will begin being shipped in the first quarter of 2023, PacBio said.
Onso, meanwhile, has a list price of $259,000. Orders for the system will be taken in the first quarter of 2023, and shipments will begin in the first half of 2023.
An external beta program that uses the testing sites of the Broad Institute of MIT and Harvard, Corteva Agriscience, and Weill Cornell Medicine will precede shipment of the Onso system, PacBio added.
